Propyl[2-(thiophen-2-yl)ethyl]amine | 847544-96-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Propyl[2-(thiophen-2-yl)ethyl]amine
• 英文别名: N-(2-thiophen-2-ylethyl)propan-1-amine
• CAS: 847544-96-1
• 化学式: C₉H₁₅NS
• mdl: MFCD11145622
• 分子量: 169.29
• InChiKey: YZBKMLGLDHXXFH-UHFFFAOYSA-N

物化性质

• 沸点：
  241.7±15.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P271,P280,P301+P330+P331,P302+P352,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P405,P501
• 危险品运输编号：
  2735
• 危险性描述：
  H302,H312,H332,H335,H314
• 包装等级：
  III

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF ROTIGOTINE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA ROTIGOTINE
  申请人：FIDIA FARMACEUTICI

  公开号：WO2010035111A1

  公开（公告）日：2010-04-01

  A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid- sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-l-methoxy- naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.

  一种制备罗蒂高定（I）及其药用可接受盐的方法，包括将式6的胺与2-噻吩乙酸钠硼氢化合物进行还原胺化反应，并利用溴化氢盐5作为中间体（II）。该方法在工业角度具有优势，因为它允许从光学活性的5,6,7,8-四氢-6-(S)-N-丙基氨基-1-甲氧基-萘烯（2）出发，以高对映体纯度获得罗蒂高定，避免使用危险的反应物、需要困难的色谱分离或生成副产物。此外，还披露了两种新的结晶形式。
• [EN] PREPARATION OF CRYSTALLINE ROTIGOTINE BASE<br/>[FR] PRÉPARATION DE ROTIGOTINE À BASE CRISTALLINE
  申请人：PLIVA HRVATSKA D O O

  公开号：WO2009063170A1

  公开（公告）日：2009-05-22

  The present invention relates to processes of preparing rotigotine form its heminaphthalene -1,5- disulfonate salt as a free base in solid cyrstalline form.

  本发明涉及制备罗蒂高定（rotigotine）的苯并-1,5-二磺酸盐作为固态结晶形式的游离碱的过程。
• [EN] NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE<br/>[FR] NOUVEAUX 2-AMINOINDANES ET 2-AMINOTETRALINES CONDENSES AU 2-AMINOTHIAZOL ET LEUR UTILISATION
  申请人：WIKSTROEM HAKAN VILHELM

  公开号：WO2000001680A1

  公开（公告）日：2000-01-13

  The invention relates to 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins having general formula (1): wherein R1 and R2, which may be identical or different, are selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 7 carbon atoms, (alkyl)cycloalkyl groups of 3 to 7 carbon atoms, alkenyl or alkynyl groups of 3 to 6 carbon atoms, arylalkyl having 1 to 3 carbon atoms in the alkyl moiety, whilst the aryl nucleus may be substituted; and n and m are 1 or 2; and the enantiomers and the acid addition salts thereof, pharmaceutical compositions containing them and their use in the preparation of medicaments having an effect on the dopaminergic system of the central nervous system and/or the circulation.

  本发明涉及具有一般式（1）的2-氨基噻唑并2-氨基茚和2-氨基四氢萘，其中R1和R2可以相同也可以不同，选自氢原子，1至7个碳原子的烷基或卤代烷基，3至7个碳原子的（烷基）环烷基，3至6个碳原子的烯基或炔基，1至3个碳原子的芳基烷基，而芳基核可以被取代；n和m为1或2；以及其对映体和酸加成盐，含有它们的制药组合物以及它们在制备对中枢神经系统和/或循环的多巴胺能作用的药物方面的用途。
• Transdermal therapeutic system and method of use thereof for treating parkinsonism
  申请人：Müller Walter

  公开号：US10251844B2

  公开（公告）日：2019-04-09

  A substantially solvent-free matrix layer containing (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.

  在粘合剂溶液中加入活性物质，将得到的含活性物质的粘合剂溶液涂覆在合适的薄片上，然后在干燥过程中除去溶剂，得到所述基本无溶剂的基质层，从而生产出含有(-)-5,6,7,8-四氢-6-[丙基-[2-(2-噻吩基)乙基]氨基]-1-萘酚的基本无溶剂基质层。
• Nucleic acids encoding engineered imine reductases
  申请人：CODEXIS, INC.

  公开号：US10308966B2

  公开（公告）日：2019-06-04

  The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

  本公开提供了具有亚胺还原酶活性的工程多肽、编码工程亚胺还原酶的多核苷酸、能够表达工程亚胺还原酶的宿主细胞，以及使用这些工程多肽与一系列酮和胺底物化合物制备仲胺和叔胺产物化合物的方法。